Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06703489 · ClinicalTrials.gov registry record · NA
Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS)
A NA study of Ventricular Tachycardia (VT), sponsored by Medtronic Cardiac Ablation Solutions.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 6
- Study locations
NCT06703489 is a NA study of Ventricular Tachycardia (VT) that is actively recruiting participants, run by Medtronic Cardiac Ablation Solutions. The registered enrollment target is 60 participants. The trial reports 6 study locations across 6 states.
The verdict
NCT06703489, a NA study of Ventricular Tachycardia (VT), is actively recruiting participants, sponsored by Medtronic Cardiac Ablation Solutions.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 6
- Study locations
Study Summary
Sphere-9 VT EFS is a prospective, multi-center, non-randomized, unblinded feasibility study. Adult subjects with recurrent, sustained, scar-related monomorphic ventricular tachycardia will be enrolled and treated with the Sphere-9 Catheter and Affera Ablation System.
Conditions Studied
Interventions
- DEVICE Sphere-9 Catheter with the Affera Mapping and Ablation System
Study Locations (6)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
New York
- Icahn School of Medicine at Mount Sinai - New York
Ohio
- Cleveland Clinic Foundation - Cleveland
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- Texas Cardiac Arrhythmia Research Foundation - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-03-18 |
| Est. Completion | 2027-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06703489
The ClinicalTrials.gov registry entry for NCT06703489 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Ablation Solutions, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ventricular Tachycardia (VT) appearing as the primary indexed condition, and to 1 intervention - of which Sphere-9 Catheter with the Affera Mapping and Ablation System is the first listed.
NCT06703489 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Massachusetts, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT06703489 about?
NCT06703489 is a clinical study titled "Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS)". Sphere-9 VT EFS is a prospective, multi-center, non-randomized, unblinded feasibility study. Adult subjects with recurrent, sustained, scar-related monomorphic ventricular tachycardia will be enrolled and treated with the Sphere-9 Catheter and Affera Ablation System.
What is the current status of trial NCT06703489?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2025-03-18. Estimated completion is 2027-01.
What conditions does trial NCT06703489 study?
This clinical trial studies the following conditions: Ventricular Tachycardia (VT).
What interventions are being tested in trial NCT06703489?
The interventions under investigation include: Sphere-9 Catheter with the Affera Mapping and Ablation System (DEVICE).
Who is sponsoring clinical trial NCT06703489?
This trial is sponsored by Medtronic Cardiac Ablation Solutions, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06703489 being conducted?
This trial has 6 study locations across Massachusetts, New York, Ohio, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.